The experimental therapy, fidanacogene elaparvovec, reduced the annualized bleeding rate of total bleeds by 71 percent. The trial compared the one-time gene therapy treatment to the current treatment for the rare blood disorder, which is a prophylaxis regimen.
Pfizer said it will share the data with regulators in 2023.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
